ImageneBio Valuation
| IMA Stock | 5.71 -0.15 -2.56% |
Above Model Estimate
Today
Macroaxis currently classifies ImageneBio's price fluctuation as Elevated. For valuation purposes, Macroaxis measures ImageneBio over a 3 months time horizon. Negative margins (-53.85%) signal that the market sees earnings risk not yet reflected in the model's forward assumptions. Extending ImageneBio's horizon generally improves valuation accuracy.
Value Estimates Divergence
ImageneBio is trading at $5.71 versus a model-derived intrinsic value estimate of $5.3 per share, reading as above model estimate. For ImageneBio, the key valuation inputs are a return on assets of -31% and a return on equity of -32%, with an added check on Probability Of Bankruptcy. Like most valuation signals, this one reflects the idea that market price and underlying value can eventually converge.| Historical | Market 5.71 | Intrinsic 5.3 | Sentiment 5.69 | Naive 6.02 | DCF 4.97 |
The intrinsic value estimate of ImageneBio stock captures the present value of expected future earnings and cash generation. The estimate depends on ImageneBio's margin trajectory, reinvestment rate, and cost of capital.
Both the upside potential and the downside risk of ImageneBio factor into a balanced assessment. The upside estimate depends on how quickly current margin or earnings headwinds resolve, while the downside reflects what happens if they persist.
The most reliable valuation for ImageneBio emerges when intrinsic-value models and market multiples point in the same direction. Some managers use ImageneBio's intrinsic value based on ongoing forecasts of ImageneBio's financial statements.
Main Profitability Drivers
ImageneBio converts revenue at a -53.85% net margin rate, while its operating margin sits at -57.54%. ImageneBio picks up roughly 3.69 percentage points of margin from sources beyond operating income. On 800,000 of revenue, ImageneBio earned 800,000 in gross profit and -52.4 Million on the bottom line. With ROE at -32.00% and ROA at -31.00%, these return measures help contextualize ImageneBio's profitability relative to its balance sheet. Some measures are moving in the right direction for ImageneBio, but current negative margins keep the overall profitability profile fragile. View ImageneBio's full profitability analysis for additional context.
ImageneBio Cash | 33.22 Million |
Cash stood at 34.97 Million as of December 31, 2025.
ImageneBio operates as a biotechnology company where value is driven by research pipelines, clinical outcomes, and regulatory approvals, forming the primary lens for valuation. Classified as a turnaround stock in Biotechnology, negative margins indicate the investment case rests on restoring operational profitability. The sections below test current market pricing against capital structure, margins, and earnings trajectory.
Total Value Analysis
The current total-value analysis for ImageneBio points to enterprise value near -68.51 M, market capitalization around 63.87 M, debt of 9.99 M, and cash and liquid equivalents of n/a as of latest reporting. Reviewing ImageneBio fundamentals is essential here — negative enterprise value can indicate either a deep value situation or a structural problem the market is pricing in.| Takeover Price | Market Cap | Debt Obligations | Cash & Equivalents |
-68.51 M | 63.87 M | 9.99 M |
Investor Information
About 16.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.48. Some equities with similar Price to Book (P/B) outperform the market in the long run. ImageneBio recorded a loss per share of 9.64. The company had not issued any dividends in recent years. The firm completed a 1:12 stock split on 28th of July 2025. ImageneBio financial framework combines liquidity support with pressured financial positioning. Profitability remains under pressure, with return on assets below breakeven in the current period.Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ImageneBio has an asset utilization ratio of 0.52 percent. This suggests that the Company is making USD0.00523 for each dollar of assets. An increasing asset utilization means that ImageneBio is more efficient with each dollar of assets it utilizes for everyday operations.Macro event markers
Discounted Cash Flow Analysis
Using the current custom levered DCF inputs, ImageneBio is worth about 4.97 per share while the market is pricing it near 5.71. The market is pricing the shares around 13.0% over the model estimate. Current assumptions include 5.82% WACC, 2.0% perpetual growth, and about -11,794.88 of next-period free cash flow. Net debt is about -24.97 Million and the terminal value makes up roughly 29.6% of enterprise value.Model Value / Share
4.97
Equity value per share from the current custom levered DCF summary row.
Market Price
5.71
Current market price used by the same scenario.
Model Premium
13.0%
Market price sits above the model output.
WACC / LT Growth
5.82% / 2.0%
Forecast horizon: 2021 to 2030Terminal value share of EV: 29.6%
ImageneBio Market Price vs. Intrinsic Value
This chart compares observed market pricing with the model-derived equity value per share across forecast periods. It also illustrates the relative premium or discount, expressed as a percentage difference between market valuation and modeled intrinsic value.
Projected Revenue and Levered Free Cash Flow
Revenue and levered free cash flow projections are presented in billions, outlining the expected financial trajectory over the modeled horizon.
Key Model Assumptions
The inputs below reflect the core assumptions applied in the valuation model, including growth expectations, discount rates, and capital structure considerations.
| Input | Current Value |
|---|---|
| Weighted Average Cost of Capital | 5.82% |
| Long-Term Growth Rate | 2.0% |
| Cost of Equity | 6.51% |
| After-Tax Cost of Debt | 3.89% |
| Debt Weighting | 26.44% |
| Equity Weighting | 73.56% |
| Net Debt | -24.97 Million |
| Enterprise Value | -784,938.79 |
| Present Terminal Value | -232,410.72 |
| Terminal Value Share of EV | 29.6% |
Forecast Detail and Valuation Progression
This table presents the underlying forecast data used in the valuation, including revenue, cash flow generation, discounting effects, and the resulting per-share value across each projected period.
| Year | Revenue | Revenue Growth | Free Cash Flow | PV of LFCF | Equity Value / Share |
|---|---|---|---|---|---|
| 2021 | 30.98 Million | 0.00% | -62.01 Million | 0.0 | 4.97 |
| 2022 | 15.62 Million | -49.59% | -75.54 Million | 0.0 | 4.97 |
| 2023 | 9.16 Million | -41.35% | -80.16 Million | 0.0 | 4.97 |
| 2024 | 3.5 Million | -61.79% | -46 Million | 0.0 | 4.97 |
| 2025 | 800,000 | -77.14% | -47.84 Million | 0.0 | 4.97 |
| 2026 | 340,244.12 | -57.47% | -353,419.95 | -333,969.59 | 4.97 |
| 2027 | 144,707.58 | -57.47% | -150,311.33 | -134,221.92 | 4.97 |
| 2028 | 61,544.88 | -57.47% | -63,928.18 | -53,943.6 | 4.97 |
| 2029 | 26,175.35 | -57.47% | -27,188.98 | -21,679.86 | 4.97 |
| 2030 | 11,132.51 | -57.47% | -11,563.61 | -8,713.1 | 4.97 |
Profitability Analysis
Reviewing ImageneBio's reported profitability metrics, ImageneBio is currently operating at a loss, with net income of -52.4 Million. The net profit margin is -53.85% and operating margin is -57.54%, with return on equity at -32.0%. Profitability trends are mixed, with some indicators improving while others continue to contract.Net Loss | First Reported 2019-12-31 | Previous Quarter -24.8 M | Current Value -6.9 M | Quarterly Volatility 6.9 M |
Macro event markers
The profitability picture for ImageneBio starts with how effectively revenue converts to earnings. Both net and operating margins are negative (-53.85% and -57.54% respectively), indicating the business is consuming more capital than it generates at current revenue levels. Margin trends and return metrics below indicate whether the earnings profile is strengthening or deteriorating. ImageneBio reports return on equity of -32.0%, reflecting negative returns on shareholder capital.
Earnings per Share Projection vs Actual
ImageneBio's forward EPS estimates provide a structured view of expected profitability based on current analyst coverage. ImageneBio generates 800,000 in revenue, establishing the scale over which earnings per share are distributed. ImageneBio's earnings per share carry more weight when cross-referenced with cash flow from operations. Trailing and forward EPS together frame ImageneBio's earnings arc, though neither alone predicts outcomes. Consensus EPS estimates for ImageneBio represent the market's baseline earnings expectation. Deviations from this consensus on report day typically drive the sharpest price reactions. ImageneBio reported estimated earnings of -0.96375 in earnings per share on 31st of December 2026. When actual results deviate from this estimate, the gap typically signals whether earnings momentum is accelerating or fading.Macro event markers
Ownership Allocation
Over half of ImageneBio's outstanding shares are owned by institutional investors. Institutional holders such as large asset managers and pension funds typically maintain these positions as part of broader diversified mandates rather than concentrated bets on any single company. Their buying and selling activity, disclosed through 13F filings, can be a useful signal for tracking changes in professional sentiment toward ImageneBio.Revenue and Profit Overview
The company reported last year's revenue of 800 K. Reported Net Loss for the year was -52.4 M with profit before taxes, overhead, and interest of 800 K.Reading the Current Signals
Negative profit margins indicate that ImageneBio's cost structure currently exceeds its revenue generation - in technology hardware and services companies, this reflects the fixed-cost intensity of the business, where volume shortfalls or rising input costs rapidly erode profitability.
Valuation Synthesis
ImageneBio operates as a business currently operating below profitability breakeven, where operating costs tied to the underlying business model outpace revenue within the technology hardware and services companies space. Negative margins are the dominant signal - the business is consuming more capital than it generates, making traditional valuation multiples unreliable. For technology hardware and services companies, this is a direct consequence of the underlying cost structure and the sensitivity of profitability to volume and pricing. Until ImageneBio demonstrates that revenue growth, margin trajectory, and product cycle dynamics can support consistent profitability, the market is likely to continue discounting the stock relative to technology hardware and services companies with more established earnings power.
For ImageneBio, the valuation signals above are most useful when compared against future operating results as new data becomes available. With margins currently negative, the critical question is whether the path to profitability is supported by revenue trends and cost discipline.
Valuation Framework, Methodology & Assumptions
ImageneBio is a micro-cap equity in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care categories. Revenue consistency stabilizes valuation context. For ImageneBio, the leading valuation metrics are P/B of 0.48; additional context comes from P/S of 79.83.
ImageneBio metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Analyst inputs may be included when coverage is available. Valuation outputs are model-derived and depend on published assumptions and reference inputs.
The analysis above is generated by quantitative models and is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an endorsement to buy or sell any security. All investing involves risk, including the possible loss of principal. Consult a qualified financial advisor before making investment decisions. See our Terms of Use for full details.
Financial data referenced in this analysis is derived from publicly available SEC filings, audited financial statements, and third-party market data providers. The intrinsic value estimate is generated by Macroaxis quantitative models that incorporate fundamental analysis, technical indicators, and risk metrics.
The methodology combines multiple analytical inputs:
- Fundamental analysis - financial statements, profitability ratios, debt structure, and cash flow metrics sourced from SEC filings and public financial reports
- Technical indicators - historical price patterns, momentum signals, and volatility measures
- Risk assessment - probability of bankruptcy models, market risk metrics, and downside scenario analysis
- Peer comparison - relative valuation against industry peers using standardized multiples
Model outputs are refreshed periodically as new financial data becomes available. Past model performance is not indicative of future results. The intrinsic value estimate reflects a point-in-time calculation and should be considered alongside other research and professional advice.
Data sourced from SEC filings (EDGAR), public financial statements, and market data providers.
Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors
ImageneBio Current Valuation Indicators
Valuation of ImageneBio is strongest when several lenses are used together: market cap, enterprise value. revenue, and cash-flow durability. The business currently sits in the Healthcare sector and the Biotechnology industry. Current pricing suggests the market is discounting specific expectations about growth trajectory, margin stability, and capital allocation. Reported values are derived from company filings, audited financial statements, and market data, and are standardized within Macroaxis quantitative models for consistency. Model outputs reflect a point-in-time estimate based on available data and assumptions and should be interpreted alongside changes in operating performance, market conditions, and forward expectations.
Popular Tools for ImageneBio Stock analysis
Positions RatingsView algorithmic ratings for individual portfolio positions based on fundamental analysis and risk-adjusted market performanceEconomic IndicatorsTop statistical indicators that provide insights into how an economy is performingBalance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratiosEquity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities